When the largest bank in the U.S. says a crisis is coming - you NEED to listen. The Wall Street Journal warns, "America's bonds are getting harder to sell."

Click here to see why Wall Street is in PANIC mode >>>

Shankar Musunuri net worth and biography

Shankar Musunuri Biography and Net Worth

CEO of Ocugen

Dr. Musunuri is a seasoned biotech veteran with more than 25 years of results-driven experience advancing and commercializing a diverse portfolio of products. Prior to co-founding Ocugen in 2013, Dr. Musunuri held leadership roles at numerous companies ranging from "Big Pharma" to novel start-up biotechs. Most recently, he founded Nuron Biotech, Inc., which he grew to a commercial company in less than three years, serving as President and CEO. Dr. Musunuri spent nearly fifteen years at Pfizer, where he gained extensive product launch and life-cycle management experience, playing a key role as Global Operations Team Leader for the most successful launch in vaccine history, Prevnar 13®. Prior to Pfizer, he was a group leader focused on Phase 3 clinical development at Amylin Pharmaceuticals.

Dr. Musunuri obtained his PhD in Pharmaceutical Sciences from the University of Connecticut and an MBA from Duke University’s Fuqua School of Business. He is a recipient of the Distinguished Alumnus Award from the University of Connecticut’s School of Pharmacy and serves on the Advisory Board of Fuqua’s Center for Entrepreneurship and Innovation at Duke University.

What is Shankar Musunuri's net worth?: The estimated net worth of Shankar Musunuri is at least $3.65 million as of January 17th, 2023. Dr. Musunuri owns 2,227,950 shares of Ocugen stock worth more than $3,653,838 as of July 27th. This net worth approximation does not reflect any other investments that Dr. Musunuri may own. Additionally, Dr. Musunuri receives a salary of $1,200,000.00 as CEO at Ocugen. Learn More about Shankar Musunuri's net worth.
How old is Shankar Musunuri?: Dr. Musunuri is currently 60 years old. There are 3 older executives and no younger executives at Ocugen. Learn More on Shankar Musunuri's age.
What is Shankar Musunuri's salary?: As the CEO of Ocugen, Inc., Dr. Musunuri earns $1,200,000.00 per year. Learn More on Shankar Musunuri's salary.
How do I contact Shankar Musunuri?: The corporate mailing address for Dr. Musunuri and other Ocugen executives is 5 GREAT VALLEY PARKWAY V, MALVERN PA, 19355. Ocugen can also be reached via phone at (484) 328-4701 and via email at [email protected]. Learn More on Shankar Musunuri's contact information.
Has Shankar Musunuri been buying or selling shares of Ocugen?: Shankar Musunuri has not been actively trading shares of Ocugen in the last ninety days. Most recently, Shankar Musunuri sold 100,000 shares of the business's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $1.28, for a transaction totalling $128,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,227,950 shares of the company's stock, valued at $2,851,776. Learn More on Shankar Musunuri's trading history.
Who are Ocugen's active insiders?: Ocugen's insider roster includes Kirsten Castillo (Director), Prabhavathi Fernandes (Director), Uday Kompella (Director), Ramesh Kumar (Director), Shankar Musunuri (CEO), Manish Potti (Director), Sanjay Subramanian (CFO), Vijay Tammara (SVP), and Junge Zhang (Director). Learn More on Ocugen's active insiders.

Shankar Musunuri Insider Trading History at Ocugen

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/17/2023	Sell	100,000	$1.28	$128,000.00	2,227,950
10/14/2022	Sell	100,000	$1.66	$166,000.00	752,540
7/14/2022	Sell	150,000	$2.72	$408,000.00	752,540
5/13/2022	Sell	125,000	$1.92	$240,000.00	752,540
3/16/2022	Sell	81,823	$2.65	$216,830.95
12/16/2021	Sell	115,000	$5.22	$600,300.00
11/16/2021	Sell	115,000	$8.04	$924,600.00
11/1/2021	Sell	115,367	$14.15	$1,632,443.05
10/15/2021	Sell	125,000	$9.80	$1,225,000.00
9/15/2021	Sell	125,000	$7.52	$940,000.00
6/7/2021	Sell	7,758	$10.94	$84,872.52	413,758
5/3/2021	Sell	195,809	$14.24	$2,788,320.16	601,809
12/12/2019	Buy	406,000	$0.34	$138,040.00	263,000

Shankar Musunuri Buying and Selling Activity at Ocugen

Ocugen Company Overview

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

Today's Range

Now: $1.64

$1.58

$1.66

50 Day Range

MA: $1.63

$1.18

$1.95

2 Week Range

Now: $1.64

$0.35

$2.11

Volume

2,389,067 shs

Average Volume

7,254,171 shs

Market Capitalization

$422.05 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.65

J.P. Morgan’s DIRE Warning

From Behind the Markets | Ad